6th DIA Cell and Gene Therapy Products Symposium in Japan

Overview

6th DIA Cell and Gene Therapy Products Symposium in Japan
“Mastering Regenerative Medicine in Clinical Practice: Solving Issues at the Industrial Stage”

Click Here to View the Program

Who should attend?

Cell therapy/gene therapy product development professionals in biopharmaceutical companies, medical devices companies, venture capital companies, regulatory agencies, or academia.

Program Committee

Yoji Sato, PhD • Head, Division of Cell-Based Therapeutic Products
National Institute of Health Sciences, Japan
Yasuko Terao, PhD • Director, External Collaboration and Portfolio Management Department
Janssen Pharmaceutical K.K., Japan
Teruyo Arato, PhD • Professor, Clinical Research and Medical Innovation Center
Hokkaido University Hospital, Japan
Masaki Kasai, PhD • Principal Reviewer, Office of Cellular and Tissue-basaed Products
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Satoru Hayata, MS •
Sobi Japan, Japan
Sumimasa Nagai, MD, PhD • Institute for Advancement of Clinical and Translational Science(iACT)
Kyoto University Hospital, Japan
Hiromi Okabe, PhD • Manager, Global Regulatory Management Group, New Drug Regulatory Affairs Dept.
Daiichi Sankyo Co., Ltd., Japan
Kazunobu Oyama, PhD •
Daiichi Sankyo Co., Ltd., Japan
Masafumi Onodera, MD, PhD • Head, Department of Human Genetics / Chief, Division of Immunology
National Center for Child Health and Development, Japan
Hiroyuki Suda, MSc • VP, Clinical Development Strategy
KORTUC Inc., Japan
Yoshie Tsurumaki • Group Manager, Cell & Gene Franchise
Novartis Pharma K.K., Japan
Akiko Ikeda, RPh • Associate Director, Regulatory Development Dept., Regulatory Affairs Division,
Janssen Pharmaceutical K.K., Japan